Gene Therapy Offers One-Time Cholesterol Fix

Eli Lilly is developing VERVE-102, a groundbreaking gene-editing therapy designed to treat high cholesterol. This experimental drug targets and switches off the PCSK9 gene in the liver, which is responsible for producing a protein that regulates cholesterol levels. The therapy is administered as a single, approximately four-hour infusion, potentially replacing the need for daily medications or regular injections.

Early research involving 35 individuals demonstrated that VERVE-102 reduced LDL cholesterol by up to 62% after just one infusion. Furthermore, over a third of participants experienced sustained lower cholesterol levels for as long as 18 months post-treatment. While promising, experts emphasize the need for further research, noting the small initial study size and that its impact on preventing heart attacks or strokes has not yet been assessed.

The Food and Drug Administration has already granted fast-track status to the study of VERVE-102. Eli Lilly intends to commence a larger Phase 2 study by the close of 2026. This innovative approach could offer a significant new option for the nearly 25 million Americans affected by high cholesterol, a major risk factor for heart disease.